Lymphoma Cancer Statistics in US 2026 | Key Facts

Lymphoma Cancer in America 2026

Lymphoma cancer remains one of the most talked-about blood cancers in the United States, quietly affecting hundreds of thousands of Americans every single year — yet it doesn’t always get the public attention it deserves. As of 2026, the numbers tell a story that is both sobering and, in certain respects, encouraging. Advances in treatment have meaningfully extended survival for many patients, and awareness is steadily growing. Still, lymphoma — which originates in the lymphatic system, a critical part of the body’s immune defense network — continues to be diagnosed in tens of thousands of people annually, spanning all ages, all backgrounds, and all corners of the country.

Understanding the lymphoma cancer statistics in the US in 2026 is not just a matter of academic interest — it is essential for patients, caregivers, policymakers, and healthcare professionals who need current, reliable data to make informed decisions. The two primary forms — Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) — behave very differently, carry distinct prognoses, and affect different demographic groups in distinct ways. Whether you are newly diagnosed, researching on behalf of a loved one, or simply looking to understand the scope of this disease in America today, the statistics compiled here from US government sources and leading cancer research bodies provide the clearest, most up-to-date picture available as of March 2026.

Interesting Facts About Lymphoma Cancer in the US 2026

Data Sources: American Cancer Society Cancer Facts & Figures 2026; NCI SEER Cancer Stat Facts (seer.cancer.gov); Cancer Statistics 2026 (CA: A Cancer Journal for Clinicians, January 2026); Cancer Treatment and Survivorship Statistics 2025 (PMC/ACS).

When you stack these numbers side by side, several things jump out immediately. First, the sheer scale: over 79,000 estimated new Non-Hodgkin Lymphoma diagnoses alone in 2026 places it firmly in the top tier of commonly diagnosed cancers in the United States. Second, the contrast between the two major types is striking — Hodgkin Lymphoma, while receiving less press, is actually the single most diagnosed cancer among American teenagers aged 15 to 19, making it far from a disease of old age. Meanwhile, Non-Hodgkin Lymphoma is overwhelmingly concentrated in adults aged 65 and older, reflecting how age-related immune decline plays a role in its development.

The survival data is where the most encouraging story lies. Follicular lymphoma, one of the most common indolent (slow-growing) NHL subtypes, now carries a 5-year relative survival rate of approximately 90%, a dramatic improvement compared to just a few decades ago. Even Hodgkin Lymphoma, once feared as a nearly untreatable diagnosis, now boasts an approximately 89% five-year survival rate — numbers that reflect decades of progress in chemotherapy, immunotherapy, and targeted treatment. That said, the fact that DLBCL — the most common aggressive NHL subtype — still carries only a 65% five-year survival rate is a clear reminder that much work remains, particularly for high-risk and elderly patients who may not tolerate aggressive treatment regimens.

Non-Hodgkin Lymphoma (NHL) Incidence & Mortality Statistics in the US 2026

Data Source: American Cancer Society Cancer Facts & Figures 2026; NCI SEER Cancer Stat Facts: Non-Hodgkin Lymphoma (seer.cancer.gov/statfacts/html/nhl.html); Cancer Statistics 2026, CA: A Cancer Journal for Clinicians.

The 2026 Non-Hodgkin Lymphoma incidence numbers reveal a disease that is both widespread and gradually being brought under better control. With 79,320 estimated new diagnoses expected across the US in 2026, NHL continues to rank among the ten most common cancers in the country. The fact that males account for 43,770 of those projected cases — compared to 35,550 females — underscores a consistent gender gap that researchers attribute to differences in immune function, hormonal factors, and environmental exposures. The age-adjusted incidence rate of 18.7 per 100,000 reflects a disease that, while common, is showing gradual signs of decline, with both incidence and mortality trending downward by less than 1% and 2% per year, respectively, based on data through 2022–2023.

What stands out even more in this data is the mortality trajectory. Nearly 20,000 Americans are still expected to die from NHL in 2026, with males bearing a disproportionately higher burden at 11,710 deaths versus 8,260 for females. However, the declining death rate trend of approximately 2% per year — outpacing the decline in new cases — is a signal that treatments are becoming progressively more effective. The prevalence figure of 835,496 people living with NHL in the US as of 2022 represents a large and growing community of survivors who require ongoing follow-up care, surveillance, and support — a point that health systems and policymakers must actively plan around as this number continues to grow in 2026 and beyond.

Hodgkin Lymphoma (HL) Incidence & Mortality Statistics in the US 2026

Data Source: NCI SEER Cancer Stat Facts: Hodgkin Lymphoma (seer.cancer.gov/statfacts/html/hodg.html); American Cancer Society Cancer Facts & Figures 2026; Cancer Treatment & Survivorship Statistics 2025, ACS/NCI.

Hodgkin Lymphoma in 2026 continues to occupy a unique position in the US cancer landscape — it is both relatively rare overall (just 0.4% of all new cancer cases) and remarkably common among a specific demographic: young adults. The most common age of diagnosis falls in the 20–34 age bracket, and HL holds the distinction of being the single most frequently diagnosed cancer in American adolescents aged 15 to 19. This demographic reality makes HL a particularly emotionally charged diagnosis — young patients in the prime of their lives, often in school or just starting careers, suddenly confronting a serious blood cancer. The average age at HL diagnosis is 39, far younger than the 65+ median seen in NHL, which requires a completely different approach to treatment planning and survivorship support.

The good news within this data is genuinely heartening. With a 5-year relative survival rate of approximately 89% for all stages combined — and 92.9% for Stage I cases specifically — Hodgkin Lymphoma is now one of the most treatable cancers in oncology. The death rate of just 0.3 per 100,000 is among the lowest of any cancer type, and both incidence and mortality continue to fall each year — declining 1.4% and 2.3% annually, respectively. Roughly 235,110 Americans were living as HL survivors as of January 1, 2025, a number that speaks to how far treatment has come over the past several decades and reinforces the importance of long-term survivorship monitoring, given that late effects of HL treatment (including secondary cancers and cardiovascular issues) can emerge years after a patient is considered cured.

NHL Subtypes & 5-Year Survival Rates in the US 2026

Data Source: NCI SEER Cancer Stat Facts: DLBCL (seer.cancer.gov/statfacts/html/dlbcl.html); NCI SEER Cancer Stat Facts: Follicular Lymphoma (seer.cancer.gov/statfacts/html/follicular.html); American Cancer Society Cancer Facts & Figures 2026; PMC — Analysis and Prediction of Relative Survival Trends in NHL Patients in the US.

The NHL subtype landscape reveals just how varied this diagnosis truly is. DLBCL — accounting for roughly 30% of all NHL cases — is the most common NHL subtype in the US and is classified as an aggressive, fast-growing lymphoma. Its 5-year relative survival rate of approximately 65% reflects the challenging nature of this disease, particularly in elderly patients or those with high-risk features. The incidence rate of 5.6 per 100,000 makes DLBCL a disease that oncologists across the country encounter regularly, and age-adjusted new case rates have been falling ~0.8% per year since 2013, a modest but meaningful improvement. In contrast, Follicular Lymphoma, the second most common subtype, is a slow-growing (indolent) disease with a dramatically better 5-year survival rate of approximately 90% and an incidence rate of 2.4 per 100,000, with new case rates declining ~1.2% per year — a trend that reflects both improved diagnosis and possible environmental or lifestyle factors.

At the extremes of the survival spectrum, Marginal Zone Lymphoma stands out with an estimated 5-year relative survival rate of approximately 92.5%, the highest of the major NHL subtypes, driven by its typically indolent behavior and good response to treatment. Mantle Cell Lymphoma and Peripheral T-Cell Lymphoma, on the other hand, remain among the most difficult NHL subtypes to treat, with 5-year survival rates that lag considerably behind the overall average. The fact that the combined 5-year NHL survival rate across all stages is approximately 74% underscores the enormous variation within this broad cancer category — making accurate subtype-specific diagnosis not just clinically important but genuinely life-determining for patients.

NHL & HL Survival by Stage at Diagnosis in the US 2026

Data Source: NCI SEER Cancer Stat Facts: Hodgkin Lymphoma & DLBCL & Follicular Lymphoma (seer.cancer.gov); American Cancer Society — Lymphoma Survival Rates by Stage (accessed 2025–2026 data); Cancer Treatment and Survivorship Statistics 2025, PMC/ACS.

Stage at diagnosis is arguably the single most powerful predictor of outcome for both Hodgkin and Non-Hodgkin Lymphoma patients. The data here makes this point with unmistakable clarity. For Hodgkin Lymphoma, patients diagnosed at Stage I face a 92.9% five-year relative survival rate — outcomes that rival many early-stage solid tumors. Yet even at Stage IV, HL survival rates remain substantially better than most other cancers at the same stage, reflecting the effectiveness of modern chemotherapy regimens and immunotherapy. The fact that only 13.3% of HL cases are diagnosed at Stage I, however, is a reminder that earlier detection remains a significant opportunity to improve outcomes further.

For NHL subtypes, the stage-survival relationship is equally stark. Follicular Lymphoma diagnosed at a localized stage carries a 5-year survival rate approaching 95–96%, while distant-stage Follicular Lymphoma still maintains an impressive ~85% — a testament to how well this indolent cancer responds to treatment even when widespread. DLBCL, being aggressive, sees a more pronounced survival drop with advancing stage, with distant-stage survival falling to approximately 57%. These numbers collectively reinforce a consistent public health message: early detection matters enormously in lymphoma. For a disease that often begins with subtle symptoms like persistent swollen lymph nodes, unexplained fatigue, or night sweats — symptoms that are easily dismissed — awareness campaigns and physician education around prompt referral could genuinely translate into lives saved each year across the United States.

NHL Incidence by Age Group in the US 2026

Data Source: NCI SEER Cancer Stat Facts: Non-Hodgkin Lymphoma (seer.cancer.gov/statfacts/html/nhl.html); Trends of Non-Hodgkin Lymphoma Incidence Among Adults in the US From 2000 to 2020, PMC, 2025.

The age distribution of Non-Hodgkin Lymphoma in the US in 2026 tells a clear and important story: this is primarily a disease of older Americans. With 57% of all NHL cases occurring in individuals over age 65 and the peak incidence age group falling between 65–74 years, NHL fits the broader pattern of cancers driven significantly by immune system aging and accumulated genetic mutations over a lifetime. The risk increases notably from the 45–54 age bracket onward, making middle age a critical window for awareness and any future screening strategies. That said, the presence of NHL in younger populations — including children, teenagers, and young adults — means clinicians and patients in all age groups should not dismiss suspicious symptoms purely on the basis of age.

What makes this age distribution particularly important from a policy and clinical standpoint is the overlap with other age-related comorbidities. Elderly NHL patients are far more likely to have heart disease, diabetes, kidney disease, or other conditions that complicate and may limit treatment options. Aggressive NHL subtypes like DLBCL — most frequently diagnosed in the 65–74 age group — may require chemotherapy regimens that older, frailer patients simply cannot tolerate at full doses, directly impacting outcomes. This reality drives ongoing research into less toxic, more targeted therapies for elderly NHL patients, and explains why the survival disparity between younger and older NHL patients remains significant even when controlling for stage at diagnosis.

Lymphoma Cancer Trends & Decline Rates in the US 2026

Data Source: NCI SEER Cancer Stat Facts — NHL & Hodgkin Lymphoma (seer.cancer.gov); Cancer Statistics 2025 & 2026, CA: A Cancer Journal for Clinicians; American Cancer Society Cancer Facts & Figures 2026.

The trend data for lymphoma in the United States through 2026 is genuinely encouraging, even as absolute case numbers remain high. Both NHL and Hodgkin Lymphoma have been on measurably declining incidence trajectories for over a decade, driven by a combination of factors — including improved risk factor management, advances in treatment leading to reclassification of previously diagnosed cases, and possible environmental shifts. The fact that mortality rates are falling faster than incidence rates for both HL and NHL is particularly meaningful: it suggests that beyond fewer people getting these cancers, treatments are also becoming dramatically more effective at keeping diagnosed patients alive longer. Hodgkin Lymphoma’s death rate decline of 2.3% per year is especially striking given how low the baseline mortality already is.

For specific NHL subtypes, the pattern holds but with some nuance. DLBCL’s mortality rate has remained stable even as its incidence inches downward, reflecting the challenge of treating this aggressive subtype despite significant therapeutic advances including CAR-T cell therapy and novel targeted agents introduced over the past decade. Follicular Lymphoma shows the most consistent improvement across both incidence and mortality metrics, consistent with its indolent nature and favorable response to modern immunochemotherapy regimens. When read together, these trends paint a picture of genuine but uneven progress — with the American cancer research and treatment community making measurable gains against lymphoma, even as the battle against the most aggressive subtypes continues.

Lymphoma Cancer Prevalence & Survivor Data in the US 2026

Data Source: NCI SEER Cancer Stat Facts: NHL & Hodgkin Lymphoma (seer.cancer.gov); Cancer Treatment and Survivorship Statistics 2025, American Cancer Society & NCI (PMC12223361).

The prevalence and survivor numbers for lymphoma in the United States heading into 2026 reflect a quiet but profound population health reality: well over one million Americans are currently living with a lymphoma diagnosis or as lymphoma survivors. The 879,290 NHL survivors and 235,110 HL survivors recorded as of January 1, 2025, represent not just medical success stories, but a massive population with ongoing and complex healthcare needs. Survivors of both types carry elevated risks for secondary cancers, cardiovascular disease, and neuropathy — particularly those treated with older chemotherapy protocols and radiation — making long-term follow-up care a critical priority that the US healthcare system must be equipped to provide.

The 2.0% lifetime risk for NHL — meaning roughly 1 in 50 Americans will receive an NHL diagnosis at some point in their lives — makes this a disease that touches nearly every American family in some way. The comparatively rare 0.2% lifetime risk for HL may seem small, but given how disproportionately it affects young people and its particular prevalence in the 15–19 age group, even this modest percentage translates into thousands of young lives disrupted each year by a serious cancer diagnosis. As survivor numbers continue to grow each year, driven by an aging population and improving treatments, the social, economic, and public health burden of lymphoma survivorship will become an increasingly prominent challenge for American healthcare infrastructure in 2026 and the decade ahead.

Lymphoma Cancer by Gender in the US 2026

Data Source: American Cancer Society Cancer Facts & Figures 2026 (cancer.org); NCI SEER Cancer Stat Facts: Non-Hodgkin Lymphoma (seer.cancer.gov/statfacts/html/nhl.html).

The gender gap in Non-Hodgkin Lymphoma is one of the more consistent and well-documented patterns in US cancer statistics. Men face a meaningfully higher burden at every level — more new diagnoses, more deaths, and a higher lifetime risk. With 43,770 projected male NHL diagnoses compared to 35,550 in females for 2026, the male-female gap amounts to roughly 8,000 additional cases in men per year. Researchers attribute this disparity to a combination of factors including hormonal differences (estrogen may have a protective immune effect), occupational exposures (males are more commonly exposed to certain pesticides, solvents, and chemicals linked to lymphoma risk), and possibly intrinsic immunological differences in how male immune cells respond to mutagenic triggers.

The mortality gap is even wider in proportional terms: men account for 11,710 NHL deaths in 2026 versus 8,260 in women — a near 42% higher male death toll. Beyond raw numbers, this reflects the fact that male NHL patients tend to present with more aggressive disease at diagnosis, may be older at presentation, and are more likely to have comorbidities that limit treatment options. The lifetime risk of 1 in 46 for men versus 1 in 55 for women serves as a useful population-level benchmark for clinicians counseling patients on risk, particularly for men over 60 who present with unexplained lymphadenopathy, persistent fatigue, or constitutional symptoms. Awareness of this gender-based risk gradient is an important tool in prompt diagnosis and early intervention.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE